S1 Fig. Beta diversity indices among groups. A) Principal Coordinate Analysis of unweighted
UniFrac distances of 16S rRNA genes representing the difference in microbial communities
among cats treated with amoxicillin clavulanic acid (blue circles), cats treated with doxycycline
(yellow circles), and healthy control cats (red circles) on days 20/28 (last day of treatment), 60,
120, and 300. B) Principal Coordinate Analysis of weighted UniFrac distances of 16S rRNA
genes representing the difference in microbial communities among cats treated with amoxicillin
clavulanic acid (blue circles), cats treated with doxycycline (yellow circles), and healthy
control cats (red circles) on days 20/28 (last day of treatment), 60, 120, and 300.
S2 Fig. Rarefaction curves for A) Chao1, B) Observed ASVs, and C) Shannon Index.
S1 Table. Clinical data of cats participating to the study.
S2 Table. Alpha diversity metrics (mean ± standard deviation) with summary statistics;
CON, healthy cats that did not receive antibiotics; AMC, cats treated with amoxicillin/clavulanic
acid for 20 days; DOX, cats treated with doxycycline for 28 days.
S3 Table. Beta diversity differences based on ANOSIM analysis. CON, healthy cats that did
not receive antibiotics; AMC, cats treated with amoxicillin/clavulanic acid for 20 days; DOX,
cats treated with doxycycline for 28 days.
S4 Table. Beta diversity differences based on PERMANOVA analysis. CON, healthy cats
that did not receive antibiotics; AMC, cats treated with amoxicillin/clavulanic acid for 20 days;
DOX, cats treated with doxycycline for 28 days.
S5 Table. Summary statistics of sequencing data describing the mean percent and standard
deviation of sequences belonging to antibiotic-treated (AMC and DOX groups) and
healthy (CON group) cats.
S6 Table. Summary statistics of qPCR data describing the mean log abundance and standard
deviation of bacterial groups belonging to antibiotic-treated (AMC and DOX groups)
and healthy (CON group) cats.